In adherance with Harvard Medical School's response to the COVID-19 pandemic, the DRSC/TRiP-FGR and DRSC-BTRR will be closing our doors by 5 pm on Wed. March 16.
Services will be unavailable for at least 6-8 weeks but leaders and staff will be reachable by email, and related resources are available at the BDSC and DGRC in Indiana, and at Addgene, and information remains available at this site.
We are focused right now on minimizing the impact of the shut-down on our activities. In the future, we expect to be able to make use of the time to help our research...
Learn about DRSC/TRiP activities focused on using CRISPR activation to develop human disease models in a recently published Q&A with our Director, Dr. S.E. Mohr, who will be a speaker this spring at an upcoming genome editing conference in Boston, MA.
We are pleased to announce that we have been funded by NIH NIGMS to form the Drosophila Research & Screening Center-Biomedical Technology Research Resource (DRSC-BTRR). The P41-funded DRSC-BTRR (N. Perrimon, PI; S. Mohr, Co-I) builds upon and extends past goals of the Drosophila RNAi Screening Center.
As the DRSC-BTRR, we are working together with collaborators whose 'driving biomedical projects' inform development of new technologies at the DRSC. At the same time, we continue to support Drosophila cell-based RNAi and CRIPSR knockout screens and related...
We here at the DRSC/TRiP are thrilled to see this study from Hilary Nicholson et al. published in Science Signaling.
The study provides a great example of how screens in Drosophila cultured cells can be used as part of a cross-species platform aimed at discovery of new targets for disease treatment. The work represents a collaboration between the laboratory of 2019 Nobel Prize winner W. Kaelin and DRSC PI N. Perrimon.
Users of TRiP RNAi and sgRNA fly stocks take note: the Weake lab at Purdue University brought to our attention that some TRiP fly stocks carry a mutant allele of seveneless. Jonathan Zirin worked with Spencer Escobedo and Vikki Weake, as well as with folks at the Bloomington Drosophila Stock Center, to quickly identify the source, sequence the mutant allele, and pubilsh a micropublication so we can get the details to the community. Bottom line, as stated in the micropublication, "The presence of the sev mutation will not generally affect the use of these stocks, as the X...
DRSC/TRiP Director Dr. Stephanie Mohr will be presenting a talk titled "Optimization of CRISPR technologies for development of Drosophila disease models" at the 4th Annual Genome Editing Congress, which is April 7 through 8, 2020, in Boston, MA.
DRSC/TRiP Director S. Mohr will be attending and presenting a poster on fly in vivo functional genomics technologies and bioinformatics resources at the 78th Annual Meeting of the Society for Developmental Biology.
The DRSC and TRiP will be represented at "the fly meeting" -- the GSA Annual Drosophila Research Converence -- in March of 2019. We look forward to attending this 60th ADRC to talk RNAi, CRISPR, and other technologies; present what's new in our three areas of focuse (cell-based studies, informatics, and in vivo studies); and provide consultation on specific projects. Please feel free to reach out if you want to be sure to connect with us at the meeting. See you in Dallas!